Please select the option that best describes you:
How do you initially treat patients with cN3 cM0 esophageal cancer?
Do you proceed with chemotherapy alone, neoadjuvant chemoRT, or definitive chemoRT? How do you communicate treatment intent to the patient?
Answer from: Medical Oncologist at Academic Institution
This is an extremely heterogenous group and requires expert multidisciplinary review to generate an individualized plan. In fact, we discussed several patients with N3 disease -- very extensive but technically locoregional lymphadenopathy -- at our Disease Management Team meeting yesterday morning.O...
Sign in or Register to read more